Project Grant R01NS142408
- Federal Grant Award Summary The University of Texas Health Science Center at Houston received a $429,000 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded April 1, 2026, with completion targeted for March 31, 2028. This research project investigates the role of skull bone marrow-derived neutrophils in aneurysmal subarachnoid hemorrhage (SAH)...
- Federal Project Grant Award Summary Aneuryst Inc. received a $492,110 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, effective September 9, 2025, with completion targeted for August 31, 2026. The award supports enzyme phenotyping research of hydroxyfasudil, a Rho-kinase (ROCK) inhibitor being investigated as a potential therapeutic...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $521,839 Project Grant to the University of California, San Diego under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 7, 2025. The award supports a five-year research initiative (through July 31, 2030) investigating the molecular mechanisms of pathogenic microglial populations in central nervous system (CNS)...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $528,810 to the University of Texas Health Science Center at Houston under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on August 1, 2025. The award funds the International Seizure and SUDEP Research Repository (INSSURR), a four-year data resource project extending through July 31, 2029, designed to address the critical gap in...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a Project Grant award of $656,879 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 1, 2025 through July 31, 2030. This award supports research investigating the mechanisms of glioma initiation by isocitrate dehydrogenase (IDH) oncogenes in...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Johns Hopkins University a $592,233 Project Grant on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This research initiative, extending through June 30, 2030, investigates the regulation of sphingolipid biosynthesis and its relationship to motor neuron disease, specifically amyotrophic lateral...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $112,297 to The Regents of the University of Colorado (University of Colorado-Denver) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award, effective August 1, 2025, through July 31, 2027, funds research investigating the impact of nutritional status—specifically docosahexaenoic acid (DHA) deficiency—on brain...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $460,625 to the University of Massachusetts Medical School on June 7, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. This exploratory research project, scheduled for completion by May 31, 2027, investigates the roles of the deubiquitylation pathway in TDP-43 (TAR DNA-binding protein 43) pathology relevant to...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Maryland, Baltimore $602,065 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on March 5, 2026, with a completion date of December 31, 2029. This project grant supports fundamental neuroscience research investigating the molecular mechanisms by which SGLT2 (sodium-glucose cotransporter 2) regulates aquaporin-4 (AQP4)...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded J. David Gladstone Institutes a project grant of $1.37M under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) effective September 1, 2025, through August 31, 2033. The award supports an eight-year research initiative focused on understanding neurovascular interactions and their role in central nervous system (CNS) diseases characterized by...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of Texas Health Science Center at Houston a $632,144 project grant effective March 17, 2026, through February 28, 2031, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds the "Systemic Lipid Metabolism After Aneurysmal Subarachnoid Hemorrhage (SLIM-SAH)" project, which investigates the role of lipid metabolites in delayed cerebral ischemia (DCI) development following aneurysmal subarachnoid hemorrhage (ASAH). The project delivers translational research services and analytical outputs including validation of lipid biomarkers for DCI prediction, functional and gene expression analysis of circulating and cerebrospinal fluid monocytes, and development of machine learning models incorporating clinical, lipid, and gene expression data to improve outcome prediction following ASAH. The research utilizes human biosamples and targeted mass spectrometry-based assays to detect key lipid metabolites including lysophosphatidic acid (LPA) and sphingosine-1-phosphate, which preliminary findings indicate are elevated in cerebrospinal fluid and plasma of DCI patients. This translational research effort addresses a significant clinical need, as DCI occurs in approximately 30 percent of ASAH patients—a condition affecting approximately 500,000 people worldwide—and contributes substantially to long-term morbidity and mortality despite existing treatment limitations.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $632.1k | 3/17/26 |